Roche puts down $75M to sign on as new partner for Ionis' dry AMD drug, following Huntington's deal
Ionis is teaming up with Roche again, this time to develop an antisense drug for dry AMD with an upfront payment of $75 million to the biotech and up to $684 million more possible on the backend.
Ionis shares $IONS spiked briefly on the news.
Initially optioned to GSK, IONIS-FB-LRx was dumped alongside inotersen during GSK’s rare disease pipeline upheaval last summer. With the bulk of its late-stage pipeline housed at Akcea, Ionis has been steadily executing mid-stage deals that allow pharma partners, including AstraZeneca and Bayer, to take over the final haul to regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
